Skip to main content
Toggle navigation
Search
Home
Back
Favorite
0
Like
Facebook
Tweet
Print
SESSION 1: HR+ BREAST CANCER
Novel Endocrine Targeted Agents (PI3, AKT, FGF)
Wednesday, April 27, 2022
9:25 AM – 9:40 AM
Speaker(s)
Otto Metzger, MD
Dana-Farber Cancer Institute; Harvard Medical School
Chestnut Hill , Massachusetts
Learning Objectives:
Identify factors leading to increased risk of recurrence and/or progression in breast cancer (BC)
Evaluate the safety, efficacy, and pharmacology of available and emerging therapies in HR+/HER2- BC
Assess recent clinical data and real-world evidence regarding optimal sequences, combinations, and clinical benefit across HR+/HER2- BC therapies
Develop personalized treatment strategies based on histological type, molecular data, clinical variables, and other prognostic factors